Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging

American Journal of Cardiology

Volumn 93, Issue 6, 2004, Pages 719-723

  Kawai, Keisuke ^a   Hata, Katsuya ^b   Tanaka, Katsuji ^b   Kubota, Yoshihisa ^b   Inoue, Ryuji ^b   Masuda, Eisaku ^b   Miyazaki, Toshiyuki ^b   Yokoyama, Mitsuhiro ^b  

^a Department of Internal Medicine   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; AGING; ARTICLE; ATTENUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; SYSTOLE; UREA NITROGEN BLOOD LEVEL;

5'-GUANYLIC ACID; ADULT; AGED; AGED, 80 AND OVER; AGING; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 1542407825     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.11.054     Document Type: Article

References (31)

1. Wilkins M.R., Redondo J., Brown L.A. The natriuretic-peptide family. Lancet. 349:1997;1307-1310.
2. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., Ogawa H., Okumura K., Mukoyama M., Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
3. Tsutamoto T., Wada A., Maeda K., Hisanaga T., Maeda Y., Fukai D., Ohnishi M., Sugimoto Y., Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 96:1997;509-516.
4. Wallen T., Landahl S., Hedner T., Nakao K., Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 77:1997;264-267.
5. Kawai K., Hata K., Takaoka H., Kawai H., Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy a potential of hormone-guided treatment. Am Heart J. 141:2001;925-932.
6. Ueda R., Yokouchi M., Suzuki T., Otomo E., Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med. 114:2003;266-270.
7. Sayama H., Nakamura Y., Saito N., Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis. 10:1999;537-540.
8. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C.J. Plasma brain natriuretic peptide concentration impact of age and gender. J Am Coll Cardiol. 40:2002;976-982.
9. Chinkers M., Garbers D.L., Chang M.S., Lowe D.G., Chin H.M., Goeddel D.V., Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature. 338:1989;78-83.
10. Nomura H., Hayashi T., Esaki T., Kanda S., Kano H., Hattori A., Iguchi A. Standardization of plasma brain natriuretic peptide concentrations in older Japanese relationship to latent renal dysfunction and ischemic heart disease. J Am Geriatr Soc. 50:2002;1504-1509.
11. McCullough P.A., Duc P., Omland T., McCord J., Nowak R.M., Hollander J.E., Herrmann H.C., Steg P.G., Westheim A., Knudsen C.W., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 41:2003;571-579.
12. Sahn D.J., Demaria A., Kisslo J., Weyman A. The Committee on M Mode Standardization of the American Society of Echocardiography recommendations regarding quantification in M mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 58:1978;1072-1083.
13. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy comparison to necropsy findings. Am J Cardiol. 57:1986;450-458.
14. Kawai K., Takaoka H., Hata K., Yokota Y., Yokoyama M. Prevalence, predictors, and prognosis of reversal of maladaptive remodeling in idiopathic dilated cardiomyopathy with intensive medical therapy. Am J Cardiol. 84:1999;671-676.
15. Honma M., Satoh T., Takezawa J., Ui M. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. Biochem Med. 18:1977;257-273.
16. Schardijn G.H., Statius van Eps L.W. Beta 2-microglobulin its significance in the evaluation of renal function. Kidney Int. 32:1987;635-641.
17. National Kidney Foundation. Clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 39:2002;S76-S111.
18. Tsutamoto T., Kinoshita M., Ohbayashi Y., Wada A., Maeda Y., Adachi T. Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure. Circulation. 90:1994;823-829.
19. Luchner A., Burnett J.C.J., Jougasaki M., Hense H.W., Riegger G.A., Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism evidence from a population-based study. J Am Coll Cardiol. 32:1998;1839-1844.
20. Wallen T., Landahl S., Hedner T., Saito Y., Masuda I., Nakao K. Brain natriuretic peptide in an elderly population. J Intern Med. 242:1997;307-311.
21. Deary A.J., Schumann A.L., Murfet H., Haydock S., Foo R.S., Brown M.J. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond). 103:2002;493-499.
22. Cheung B.M., Brown M.J. Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension. J Hypertens. 12:1994;449-454.
23. Cheung B.M. Plasma concentration of brain natriuretic peptide is related to diastolic function in hypertension. Clin Exp Pharmacol Physiol. 24:1997;966-968.
24. Shea P.H., Maher J.F., Horak E. Prediction of glomerular filtration rate by serum creatinine and beta 2- microglobulin. Nephron. 29:1981;30-35.
25. Bianchi C., Donadio C., Tramonti G., Consani C., Lorusso P., Rossi G. Reappraisal of serum beta2-microglobulin as marker of GFR. Renal Fail. 23:2001;419-429.
26. Jovanovic D., Krstivojevic P., Obradovic I., Durdevic V., Dukanovic L. Serum cystatin C and beta2-microglobulin as markers of glomerular filtration rate. Renal Fail. 25:2003;123-133.
27. Ohashi M., Fujio N., Nawata H., Kato K., Ibayashi H., Kangawa K., Matsuo H. High plasma concentrations of human atrial natriuretic polypeptide in aged men. J Clin Endocrinol Metab. 64:1987;81-85.
28. Supaporn T., Sandberg S.M., Borgeson D.D., Heublein D.M., Luchner A., Wei C.M., Dousa T.P., Burnett J.C. Jr. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′, 5′- nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 50:1996;1718-1725.
29. Giannessi D., Andreassi M.G., Del Ry S., Clerico A., Colombo M.G., Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest. 24:2001;8-16.
30. Shock NE. Normal human aging: The Baltimore Longitudinal Study of Aging: NIH Publication No. 84-2450. Bethesda, MD: NIH, 1984:5-18.
31. Pidgeon G.B., Richards A.M., Nicholls M.G., Espiner E.A., Yandle T.G., Frampton C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension. 27:1996;906-913.